Vir Biotechnology Closes $172.5 Million Public Offering, Underwriters Fully Exercise Option
VIR has more than doubled off its 52-week low of $4.155.
Summary
Vir Biotechnology announced the closing of its public offering, raising approximately $172.5 million in gross proceeds after underwriters fully exercised their option for additional shares.
Key Events · Financing and Capital Events · VIR
-
Public Offering Closed
The public offering of common stock, initially announced on February 26, 2026, officially closed on February 27, 2026.
-
Significant Capital Raised
Vir Biotechnology received aggregate gross proceeds of approximately $172.5 million from the offering.
-
Underwriters' Option Fully Exercised
The underwriters fully exercised their option to purchase an additional 2,647,058 shares, bringing the total shares sold to 20,294,117 at $8.50 per share.
Analysis · VIR · Life Sciences
This filing announces the successful closing of Vir Biotechnology's public offering, which was initially disclosed on February 26, 2026. The full exercise of the underwriters' option for additional shares, bringing the total gross proceeds to $172.5 million, represents a significant capital infusion for the company. While the offering is dilutive, securing this substantial funding strengthens the company's balance sheet and provides capital for general corporate purposes, potentially supporting ongoing research and development, including the recently announced collaboration with Astellas for its lead prostate cancer drug.
At the time of this filing, VIR was trading at $8.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $4.16 to $10.94. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.